ON 2 AND 3 JUNE WAS HELD IN THE CITY OF AMSTERDAM, NETHERLANDS, THE MEETING OF THE INTE...
Wednesday June 5, 2019
On 2 and 3 June was held in the city of Amsterdam, Netherlands, the meeting
of the International Program Regulators Pharmaceutical Products (IPRP, for
its acronym in English) under which the ANMAT was elected unanimously as
new member.
Incorporating a significant acknowledgment for the National Administration,
as the IPRP is composed of 18 health authorities including the countries of
high health surveillance and the United States of America, Japan,
Australia, Canada and New Zealand, as well as the European Union, among
others. The program was created in January 2018 with the aim of promoting
convergence of regulatory approaches to medicinal products for human use,
and emerged as a result of the consolidation of the International Forum of
Regulators Pharmaceutical (IPRF) and the International Program Regulators
Generic Drugs (IGDRP)
During the meeting, the ANMAT presented the lines of action and regulatory
challenges the body, according to its Institutional Strategic Plan
With this new membership, the ANMAT increases its participation in the
spaces of convergence and regulatory harmonization, and strengthens its
regional and global leadership as the national regulatory authority.
On 2 and 3 June was held in the city of Amsterdam, Netherlands, the meeting
of the International Program Regulators Pharmaceutical Products (IPRP, for
its acronym in English) under which the ANMAT was elected unanimously as
new member.
Incorporating a significant acknowledgment for the National Administration,
as the IPRP is composed of 18 health authorities including the countries of
high health surveillance and the United States of America, Japan,
Australia, Canada and New Zealand, as well as the European Union, among
others. The program was created in January 2018 with the aim of promoting
convergence of regulatory approaches to medicinal products for human use,
and emerged as a result of the consolidation of the International Forum of
Regulators Pharmaceutical (IPRF) and the International Program Regulators
Generic Drugs (IGDRP)
During the meeting, the ANMAT presented the lines of action and regulatory
challenges the body, according to its Institutional Strategic Plan
With this new membership, the ANMAT increases its participation in the
spaces of convergence and regulatory harmonization, and strengthens its
regional and global leadership as the national regulatory authority.